KLARICID

This brand name is authorized in Brazil, Ecuador, Japan, Mexico, United Kingdom

Active ingredients

The drug KLARICID contains one active pharmaceutical ingredient (API):

1 Clarithromycin UNII H1250JIK0A - CLARITHROMYCIN

Clarithromycin is a semi-synthetic derivative of erythromycin A. It exerts its antibacterial action by selectively binding to the 50s ribosomal sub-unit of susceptible bacteria preventing translocation of activated amino acids. It inhibits the intracellular protein synthesis of susceptible bacteria. Read about Clarithromycin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
Klaricid 250mg Tablets	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J01FA09	Clarithromycin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01F Macrolides, lincosamides and streptogramins → J01FA Macrolides
Discover more medicines within J01FA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 500204405159319, 500204408131318, 500204409138316, 500204501115319, 500204502111317
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 23.132-1-07-07, 25.087-04-03, 25.098-04-03, 25.100-04-03, 29227-04-10
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 19304, 19305, 24568, 24569, 24570, 27807, 32540
Country: JP	医薬品医療機器総合機構	Identifier(s): 6149003F1023, 6149003F2020
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 086M91, 239M94, 335M93, 350M97